Amplatzer Amulet Left Atrial Appendage Occluder
ABBOTT MEDICAL · Decision date Oct 23, 2025
What did the FDA decide?
FDA records P200049/S013 as a supplement to PMA P200049, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 23, 2025.
FDA approval order statement
parametric release for the specified chamber/cycle at Steris AST (Minneapolis, MN).
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200049/S013
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NGV
- Decision code
- OK30
- Decision date
- Oct 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, appendage closure, left atrial.
- Applicant
- Abbott Medical
- Product code
- NGV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P200049/S012 · Related supplement
Amplatzer Amulet Left Atrial Appendage Occluder
P200049/S013 received
Application receipt date recorded by FDA.
P200049/S013 · FDA decision
30-Day Notice
P200049/S014 · Related supplement
Amplatzer Amulet Left Atrial Appendage Occluder
P200049/S015 · Related supplement
Amplatzer Amulet Left Atrial Appendage Occluder
P200049/S016 · Related supplement
Amplatzer Amulet Left Atrial Appendage Occluder (Amulet)
P200049/S017 · Related supplement
Amplatzer Amulet Left Atrial Appendage Occluder
P200049/S018 · Related supplement
AmplatzerTM Amulet Left Atrial Appendage Occluder
P200049/S021 · Related supplement
Amplatzer Amulet Left Atrial Appendage Occluder
Timeline entries are records held by MedtechLedger for P200049. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200049
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S012 | ABBOTT MEDICAL | PMA supplement | Sep 18, 2025 | FDA |
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S014 | ABBOTT MEDICAL | PMA supplement | Dec 23, 2025 | FDA |
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S015 | ABBOTT MEDICAL | PMA supplement | Feb 12, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Feb 24, 2026 | FDA | |
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S017 | ABBOTT MEDICAL | PMA supplement | Mar 19, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA | |
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S021 | ABBOTT MEDICAL | PMA supplement | Aug 28, 2026 | FDA |
Explore the linked device profile
Other records with product code NGV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA supplement | Aug 28, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Aug 21, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Jul 21, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | May 18, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Apr 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P200049/S013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





